Income Statement (NKARTA)

Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the company, MarketBeat reports. One analyst has rated t… [+3282 chars]...

Bank of America Corp DE lifted its position in shares of Nkarta, Inc. (NASDAQ:NKTX – Free Report) by 110.1% during the fourth quarter, Holdings Channel reports. The firm owned 380,444 shares of the c… [+3742 chars]...

Nkarta (NASDAQ:NKTX – Free Report) had its price target decreased by Mizuho from $16.00 to $14.00 in a research report report published on Tuesday,Benzinga reports. Mizuho currently has an outperform… [+3821 chars]...

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea… [+7063 chars]...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations & Market Opportunity Insight 2025" has been added to Resea… [+7537 chars]...

• Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors
• David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corpo… [+9990 chars]...
  Read more